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ABSTRACT
We have determined the sequence of the first 1371 nucleotides at
the 5' end of the genome of mouse mammary tumor virus using molecularly
cloned proviral DNA of the GR virus strain. The most likely initiation
codon used for the gag gene of mouse mammary tumor virus is the first
one, located 312 nucleotides from the 5' end of the viral RNA. The 5'
splicing site for the subgenomic mRNA's is located rv 288 nucleotides
downstream from the 5' end of the viral RNA. From the DNA sequence the
amino acid sequence of the N-terminal half of the gag precursor protein,
including plO and p21, was deduced (353 amino acids).
INTRODUCTION
Several interesting regions of the genome of mouse mammary tumor
virus (MMTV) have been sequenced recently. These include the long termi-
nal repeats (LTR) of exogenous and endogenous proviruses of two diffe-
rent strains, C3H and GR. (1-4). The LTR contains the signals for ini-
tiation of viral RNA synthesis and for polyadenylation. The 5' terminus
of MMTV RNA has been mapped (5-8) and the 3' end has been sequenced
(9). The LTR also contains the DNA sequences necessary for the regula-
tion of viral RNA synthesis by glucocorticoids (3, 5, 10, 11, lla, lib).
The sequences have been mapped more precisely between "- 100 and "/200
nucleotides upstream from the initiation site of RNA synthesis (8). One
or more binding sites for the glucocorticoid receptor complex have been
localized in the LTR (12-17). Furthermore the env region including the
3' splicing site for the env mRNA has been sequenced (18, 18a). Most
recently the 5' (19) and 3' (19,20) splicing sites for the 1.7 kb mRNA
potentially coding for the LTR gene product have been identified.
Information on the 5' splicing site of env mRNA and on the gag region
was so far not available. Many laboratories have encountered
considerable difficulties in molecular cloning of this region of the
MMTV genome. Recombinant plasmids or bacteriophages containing DNA
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fragments from this area seem to be generally underrepresented in gene
libraries and are difficult to propagate in different host cells (7,
18a, 21).
In this paper we report the nucleotide sequence of the 1.1 kb Pst I
fragment covering the 5' untranslated region and about half of the gag
gene of the exogenous GR-MMTV. Using the Si nuclease mapping technique
the 5' splicing site for the subgenomic mRNAs has been identified. From
the sequence data presented here and the analysis of the gag precursor
protein labeled with myristic acid (22) it seems most likely that the
first AUG in position 313-315 is used for the synthesis of the gag pre-
cursor polypeptide.
MATERIALS AND METHODS
Generation of MMTV subclones for sequencing
From the pBR 322 recombinant clones containing either the 1.1 kb
Pst I fragment or the 3.8 kb Bam HI - Xho I fragment of MMTV (3, 8), the
MMTV sequences were cut out by the appropriate restriction enzyme and
isolated by electroelution from normal agarose or by phenol extraction
from low gelling temperature agarose gels. The isolated fragments were
digested with the restriction enzymes (Biolabs Inc.) Rsa I or Hae III,
treated with E. coli DNA polymerase (Klenow enzyme A, Boehringer) and
cloned into the Hinc II restriction site of M13mp7. One of the clones
was obtained by digestion of a recombinant M13mp8 phage with DNAase I
according to the procedure of Hong (23).
DNA sequencing
The sequence of the M13 recombinant phages was determined by the
chain termination method of Sanger (24). To obtain the sequence in the
region where no recombinant phages covering both DNA strands were avail-
able, the chemical degradation method of Maxam and Gilbert (25) was
used.
Preparation of RNA
Total cellular RNA was extracted from tissue culture cells by the
hot-phenol procedure (26). Poly(A)-containing RNA was isolated by
oligo(dT)-cellulose column chromatography.
S1 nuclease mapping
The 2.7 kb Pvu II fragment of plasmid pBX (8) was purified by
electrophoresis on a low-melting agarose gel.1.3 pug of this DNA were
3'end labeled in the second nucleotide by incubation with 10 ,iCi of
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(alpha-32P) dATP (specific activity nv 400 Ci/mmol; Radiochemical Center,
Amersham), 0.1 mM dCTP and Klenow DNA polymerase for 5 hrs at 16C
(24). The DNA probe was coprecipitated with the RNA, and the Si analysis
was performed according to Favaloro et al. (27), with some modifications
(8). Gel electrophoresis on neutral and alkaline agarose gels was done
as described by Favaloro et al. (27); 6% polyacrylamide-7M urea
sequencing gels were performed as described by Sanger et al. (24). Size
marker DNA fragments were labeled at their 5' ends with (gamma-32P) ATP
and T4 polynucleotide kinase (Boehringer). The dried gels were exposed
at -70°C with Kodak X-Omat AR films and intensifying screens.
RESULTS
Sequencing strategy
The MMTV DNA subclones used in this study were derived from a
lambda recombinant phage containing an insert of 9 kb (lambda MMTV-GR
clone H, 28) comprising the complete genetic information of MMTV and one
LTR in a permuted arrangement. The two relevant Pst I fragments of 1.45
kb containing the LTR and of 1.1 kb containing the adjacent gag region
were subcloned in the plasmid pBR 322. The nucleotide sequence of the
1.45 kb Pst I fragment has been reported previously (3). At its 3' end
it contains 268 nucleotides of untranslated leader sequence (7, 8).
Subclones of the 1.1 kb Pst I fragment were generated in the bacterio-
phage M13 for sequencing. The sequencing strategy is shown in Figure 1.
All sequences indicated by an arrow were obtained by the method of
Sanger (24) using different M13 vectors. The two sequences marked with a
dot were obtained using the technique of Maxam and Gilbert (25). As
shown in Figure 1 the whole fragment has been sequenced on both strands
and on overlapping clones.
The DNA sequence of the 1.1. kb fragment
Figure 2 shows the nucleotide sequence of the 3' end of the 1.45 kb
Pst I fragment and of the total 1.1 kb Pst I fragment, starting at the
unique site of initiation of viral RNA synthesis described previously
(8). The terminally repeated sequence (R) beginning at the cap site
(position 1) (GCAACAGTCCT. ) was previously found at the 3' end of
viral RNA (9). The viral LTR ends within the Pvu II recognition site at
position 133. The sequence complementary to the 3' end of tRNAlYs starts
in position 136. This sequence allows the binding of this tRNA to be
used as a primer in the reverse transcriptase reaction. In several
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Figure 1. Partial restriction map and sequencing strategy of the MMTV
DNA. The upper part of the figure shows the position of the sequenced
DNA within the MMTV provirus. Indicated as well are the restriction
sites used in generating the cloned DNA fragments for sequencing and the
number of nucleotides sequenced downstream of the Pst I restriction site
next to the left LTR. The lower part shows the sequenced DNA fragments.
Generally the sequence was determined by the dideoxy chain termination
method (24) except the ones denoted by a dot, where the sequence was
obtained with the method of Maxam and Gilbert (25).
LTR = Long terminal repeat
H = Hae III, P = Pst I, Pv = Pvu II, R = Rsa I
retroviruses pyrimidine-rich repetitive sequences have been implicated
in the dimer linkage structure found between two viral RNA molecules
close to the 5' end (29, 30). Such a structure is found between nucleo-
tides 435-442 and 445-452 from the 5' end of the viral RNA.
The analysis of the sequence for its coding capacity revealed a
single open reading frame starting with the first possible initiation
codon (ATG) 313 nucleotides from the initiation site of viral transcrip-
tion and running until the end of the fragment (353 amino acids) there-
fore covering approximately half of the gag gene. The second possible
initiation codon in this frame is located in position 502 of the
sequence. Initiation codons present in the two other reading frames are
followed by frequent termination signals and are therefore probably not
functional.
Determination of the 5' splicing site
It has been shown previously that the subgenomic mRNA coding for
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ALA TO HAL LEU TH PIE ME SER ARC AL PIE VAL SEE VAL ARC HIS PRO HK SER ALA
CCAACACTCCTAA CATTCTTCTCTCCTCTCTTTCTCTCTCTTCCCCATCCCCTCTCCCCT
+ 1i 23 36 43 56 66
+1
ARC HIS LED SER PIE TM PHE GU CM A.m PM M LILEI PRO HL TIE LED ARC SER
CCTCACTTATCCTTCACTTTTEACACCCTCCCCCCCCACATCCCCCTCACCCTCACCTCC
73 U 91 1" 116 121
ALA ASP CYS TLY SER TIP ARC PRO ASN A6 ASP PRO AC ILE SER ASP PRO CYS LED TYR
CCCCACTCCCCCACCTCCCCCCCCAACACCCACCCTCCCATAACTCACCCTTCTCTTTAT
136 PV II 146 156 163 171 186
PHE TTR TYR PHE VAL PHE VAL LED PHE CTS LEU TYR LEU HAL TIP LEU SEE SEE 6LI CLU
TTCTACTATTTTCTCTTCCTCTTCTTTTCTCTCTATCTTCTCTCCCTATCATCACAACAC
196 266 216 226 236 241
ARC ASN CLY LED t UT CLY ASH CTS SER LED ALA TYE CLY CLU CLU HAL CLY TYR CLY
CCCAACCCACTEACEACACCCAACTCCACTCTCCCCTACCCACAACACCTACCTTACCCT
254 266 23I 336
AL PRO LEU ASP 1iii CIT HL SER CLY SEE LYS CLY WII LYS LEU PIE HAL SEE AL LEU
GTC CATTCCATUCA CCTCTCCCCCTCAAAACCCCACAAACT CTTTCTTTCTCTTTTA
316 326 336 346 351 360
CLN ARC LE LEU SER CLU ARC CLY LED HIS HAL LYS CLU SEE SER UT ILE LU PIHE TYR
CAAACCCTCCTCTCACACACCCCTETTCATCTCAACCACACCACCACAATACACTTTTAT
371 386 396 466 416 426
WI PIE LED ILE LS HAL SEE LEU CLY PIE M LS LS CLU ASP LEU ASN LEU CLN ASP
CACTTTCTCATAAACCTTTCCCTTCCTTTCCCCAACAACCACCACTTCAATTTACAACAT
3 -- .4 46 471 483
lRP LYS AC HAL CLY AC CLU IET LYS LS TTR MA ALA ASP ASP CITHU ASP SER ILE
TCCAAAACCCTACCAACACAAATCAACAAATATCCACCCACCATCCCACACATACCATA
496 566 516 526 531 546
PRO LS WIN ALA TYR PRO ILE TIP LEDWL LEU ARC WLU ILE LEUD CLUIW SER ASP
C C A A A C C A C C C C T A C C C C A T T T C C C TT C AC T T A AC AC A C A T A T T A A-C AC A A C A C T C AC A T
55 5U 573 56 596 636
LEU HAL LEU LED SR ALA CLU ALA LS SEE HAL T CLU CLU CLU LE CLU CLU CLY LED
TTCCTCTTACTATCCCCTCACCCCAACTCTCTCACTCAACAACACTTACAACAACCTTTA
616 62 636 646 653 666
TH CLY LEU LEU SER ALA SEE SE CLIN CLU LYS UTH TTE LY TH ARC CLY UT ALA TTE
ACCCCCCTACTATCACCAACTTCACAACAAAAAACTTATCCCACCACCCCAACACCATAT
671 66 69 711 711 726
ALA CLU ILE ASP UT CLU ALA ASP LYS LEU SKE CLU HIS lIE TYR ASP OLD PRO TYR CLU
C ACAAATACACACACACCCACACAAATTCTCTCAACA C ATT TATCATCAA CC ATATCAA
736 74 756 766 776 781
CLU LYS CLU LYS ALA ASP LYS AN CLU LU LYS ASP HIS HAL ARC LYS HAL LYS LYS ILE
CAAAACCACAACCCACATAAAAATCACCAAAACCACCATCTTACAAACCTAAACAAAATA
796 m8e 616 826 831 844
YAL CLI ARC LYS CID ASN SEE CLU HIS LYS ARC LS CLU LYS ASP CLN LYS ALA PHE LEU
CT ACAAACAAAACAAAATACTCAACATAACACAAAACACAACCATCAAAACC C TTT TA
8S1 8Us VI83 396 966
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ALA THR ASP TIP ASN ASP ASP ASP LEU SER PRO CLU ASP TIP ASP ASN LEU CLU 6LU GLN
GCCACAGATTGCAACCATCATCACCTCTCCCCTCACCATTCCATAATTTCCACCAACAA
911 926 931 946 956 980
ALA ALA HIS TYR HIS ASP ASP ASP CLU LEU ILE LEU PRO VAL LYS ARC LYS VA HAL LYS
6CCCCACATTATCATCATCATCATCACTTCATCCTTCCACTAAAAA6CAA6CT6CTTAAC
971 981 996 1616 1t11 1121
LYS LYS PRO LEU ALA LEU ARC ARC LYS PRO LEU PRO PRO VAL TLY PHE ALA CLY ALA MET
AAGAAACCTCTCCCACTCACAACCAAACCCCTCCCTCCCGTACCTTTTCCACCACCAATC
1631 1646 1656 1161 1176 1686
ALA CLU ALA ARC CLU LYS CLY ASP LEU THR PHE THR PHE PRO VAL AL PHE MET GLY GLU
GCACA66CCA6CCAAAACCCAGATTT6ACTTTTACCTTTCCTCTACTTTTTATCCCACAA
1191 1166 1111 1121 1136 1141
SER ASP ASP ASP ASP THR PRO AL TIP GLU PRO LEU PRO LEU LYS TOE LEU LYS GLU LEU
ACT GATCATCATCATACAC CTCTT T GCCAACC CTCCCATTCAAAA CCT TAAAACAACT A
1158 1161 1170 1181 1191 1260
CLN SER ALA VAL ARC TOE NET CLY PRO SER ALA PRO TYR TOE LEU CLU VAL A ASP MET
CAATCCGCAGTTACCACTATCCCACCATCTCCTCCATACACCTTCCAGCTCCTACACATG
1211 1226 1231 1246 1251 1266
VAL ALA SER CLN TRP LEU THR PRO SER ASP TIP HIS CLN THR ALA ARC ALA THR LEU SER
CTAGCTAGTCACTCCCTCACCCCCACTCATT6CCACCAAACACCCACACCTACCTTATCC
1276 1286 1296 1361 1316 1321
PRO CLY ASP TY VAL LEU TIP ARC TOE CLU TYR CLU 6LU LYS SER LYS GLU
C C T C C CG A T T A T C T T T T A T CGG A C A A C T C A A T A T C A A C A A A A A A G T A A A C A C
1336 1346 1351 1366 1371 9
Figure 2. Nucleotide sequence of the first 1371 nucleotides of the 5'
end of the MMTV genome and deduced amino acid sequence.
the envelope glycoprotein hybridizes only very weakly with the 1.1 kb
Pst I fragment sequenced, while it is initiated within the left LTR, 268
nucleotides upstream of the Pst I site (7, 8). It is therefore very
likely that the 5' splicing site is located within the sequenced regions
in the vicinity of this Pst I site.
This was demonstrated by the Si mapping method (31) using an end-
labeled probe (32). This technique allows one to measure directly the
distance of the splicing site from a labeled restriction site in the
DNA. We used as a probe a 2.7 kb DNA fragment isolated after digestion
with Pvu II of the plasmid pBX (8). It contains MMTV DNA sequences from
the Pvu II site (located 134 nucleotides from the cap, 8) to the Xho I
site located \ 1.4 kb downstream, plus pBR 322 sequences. The MMTV por-
tion was labeled with (alpha-32P) dATP at the 3' end of its minus strand
(Fig. 3) and annealed with RNA from infected or transfected cells. After
digestion of the hybrids with Si nuclease, the protected duplex frag-
ments were analysed by electrophoresis on a 6% polyacrylamide sequencing
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Pv Pst Pst Xh/Sal
DNA-T BR
---%-%*RNA STRAND)
cap
DNA -STRAND * -
Sl -PROTECTED:
- J' 1.4 Kb
RNA 9 Kb +
RNA-4.4Kb -v 154 nucl.RNA 4.4 Kb+
Figure 3. Experimental design for determination of the 5 splicing
site. 3'-32P-labeled probe was a 2.7 kb Pvu II fragment of the plasmid
pBX (8), where the MMTV DNA was labeled in the minus strand at the Pvu
II site (the other 3'-end label was in plasmid DNA).
gel (Fig. 4). For reference 5'-32P end-labeled SV40 DNA fragments were
electrophoresed in a parallel lane (1). A major fragment of rv 154
nucleotides was protected by RNA of L cells that had acquired cloned
WMTV DNA by transfection (28) (lane 2). The same fragment was also pro-
tected by RNA of the GR tumor cell line (lanes 3 and 4). Its abundance
was much less than in transfected cells, in agreement with our previous
observation (28, 33) that the relative amounts of subgenomic mRNA, as
compared with full-length 9 kb RNA, are higher in transfected cell
clones than in GR cells. This result locates the 5' splicing site of the
major subgenomic RNA at rv 154 nucleotides downstream of the T of the Pvu
II site, at position v289 from the cap. An analysis of the nucleotide
sequence of this area (Fig. 2) reveals the presence of a possible 5'
splicing consensus sequence (34) AG/GTAGG, where cleavage would occur
after the G at position 288. A possible alternative site is located 4
nucleotides downstream from this site. The heavily labeled band near the
origin in Figure 4 is the fragment of about 1.4 kb that is protected by
the 9 kb MMTV RNA, as shown more clearly in Figure 5. RNA from untrans-
fected L cells did not protect any detectable DNA fragment (lane 5). The
multiple fainter bands in slot 2 comigrating with bands in slots 3 and 4
probably represent additional Si-sensitive sites in the RNA-DNA
duplexes. Inspection of the sequence data (Fig. 2) in the relevant area
suggests that at least some of them may be due to local denaturation of
the duplex in (A+T) rich regions leading to Si sensitivity under the
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4 5 Figure 4. Determination of the 5' splicing site.
The experimental design and the 3'-32P-labeled DNA probe
are described in the legend to Figure 3. Approximately
20 ng of DNA probe per 25 pjg total RNA were incubated
for annealing. Hybrids were digested with Si nuclease
and analyzed on a 6% sequencing gel as described in
Materials and Methods. Hybridization reactions included
the following RNA's. Lane 2: 25 ,ug of total RNA from an
L cell clone (H2-3) transfected with the 9 kb exogenous
GR-MMTV insert (28). Lanes 3 and 4: 5 ug of poly
(A)-containing RNA plus 45 pg of poly(A)-minus RNA from
the GR tumor cell line. Lane 5 50p,g of Ltk-total RNA.
All cells were grown for 20 hrs in medium containing
10-6 M dexamethasone before RNA extraction. Lane 1:
5'-32P-labeled marker fragments of SV40 DNA digested
with Eco RII. One single film exposure is shown. The
shade above nucleotide 200 in lane 5 is an artefact of
the exposure.
t2f -
126 -
101
88
conditions of digestion used (1000 units/ml, 35 min at 37C). Likewise
the fragment of -v 250 nucleotides (position 390) might be due to Si
digestion between a 5 bp inverted repeat when a potential cruciform
structure could be formed. In other cases we cannot exclude the exist-
ence of alternative minor 5' splicing sites, since the sequence data
reveal the presence of variants of a consensus sequence (34). In any
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case, infected and transfected cells show a coincidence of minor
Si-sensitive sites, except for one. This observation supports the notion
of colinearity between viral RNA and cloned MMTV DNA (see below). It is
noteworthy that the only discrepancy (fragment of Xv 305 nucleotides,
position 443) maps in the middle of an 8 bp direct repeat separated by 2
T' s, which had been tentatively identified as the dimer linkage
structure (see above).
Colinearity of the cloned DNA with RNA from infected cells
Other laboratories reported the observation that attempts to clone
MMTV DNAs of different origins very often yielded recombinant DNA
molecules containing rearrangements and deletions in the region of the
1.1 kb Pst I fragment (7, 21). The 9 kb insert of recombinant lambda DNA
from which the subclones used for sequencing were derived was considered
to be a complete copy of MMTV DNA based on the following evidence. In
transfected cells we found MMTV RNA and precursor proteins that
comigrated electrophoretically with the respective viral products
isolated from MMTV-infected cells (28, 35, 36). However this assay for
biological activity could not detect silent deletions or rearrangements
in the 5' noncoding region or small in frame deletions in the gag coding
part of the DNA.
The Si nuclease assay described above was used to test the extent
of colinearity in the 5'-proximal 'v 1.5 kb of the genome between the
cloned DNA and RNA from infected cells. After annealing of the RNAs with
the 2.7 kb Pvu II fragment carrying a 3' end label in the minus strand
(Fig. 3) and digestion with an excess of Si nuclease at 37°C, the
protected duplex fragments were analyzed by electrophoresis on neutral
or alkaline agarose gels (27). Figure 5 shows that DNA fragments "V1.4
kb long, corresponding to the entire MMTV DNA portion of the probe, were
protected by both RNAs, whether from cells transfected with the 9 kb
cloned DNA (lanes 1 and 1') or from the virally-infected GR tumor cell
line (lanes 2 + 3 and 2' + 3'). RNA from untransfected cells did not
protect any distinct DNA bands (lanes 4 and 4'). Under the conditions
used, discontinuities like insertion or deletion loops, as well as more
complex rearrangements, would lead to Si-sensitive sites in both strands
(31) in at least a fraction of the molecules, and therefore to DNA
fragments shorter than 1.4 kb. The only distinct fast-migrating band in
Figure 5 is the DNA fragment of vv154 nucleotides protected by spliced
RNA (see Fig. 4), which is particularly abundant in transfected cells.
6951
Nucleic Acids Research
M 1
VW
5g
2.05 -
1.96 W
1.62 -
1.39-
.91 - f
.71 -
.48- 4
.*A
2 3 4 M 1' 2 3 4
..-49
2.05:_1.96
1.62 -
1.39 -
.91-
.71-
.48-
- 4_pU1
Figure 5. Colinearity of the cloned DNA with RNA from infected
cells. Approximately 20 ng of probe was annealed with 25 yg of RNA;
hybrids were digested with Si nuclease and aliquots were electrophoresed
in neutral (samples 1-4) or alkaline (samples 1'-4') 1% agarose gels as
described in Materials and Methods. Lanes 1 and 1': RNA from an L cell
clone (H2-3) transfected with the 9 kb exogenous GR-MMTV insert (28).
Lanes 2, 2' and 3, 3': RNA from the GR tumor cell line. Lanes 4 and
4': RNA from Ltk- cells. All cells were grown for 20 hrs in medium
containing 10-6 M dexamethasone before RNA extraction. Lane M : 5 _32p_
labeled marker fragments of A wt DNA digested with Eco RI and Hind III.
We therefore conclude that cells transfected with the 9 kb cloned MMTV
DNA insert synthesize MMTV RNA that is largely colinear with GR RNA.
DISCUSSION
Starting from a biologically active lambda recombinant phage carry-
ing the complete genetic information of GR-MMTV we have subcloned and
sequenced the region corresponding to the first 1371 nucleotides at the
5' end of the viral genome. This is the region of MMTV DNA which has
been difficult to clone in several laboratories and which has been pro-
posed to contain a "poison" sequence (21, 18a). Also in our laboratory a
certain number of difficulties arose in the handling and subcloning of
the subgenomic DNA fragments containing this area of the viral genome.
In M13mp7 phages containing only the first ^v 400 nucleotides of the Pst
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I fragment (0-400, Fig. 1) the insert was always present in only one
orientation. When sequences to the left or the right of this area were
also present the fragments were clonable in both orientations. Frequent
deletions of discrete length ((400 bp) have also been observed in the
course of the experiments. Despite these difficulties we ended up with a
series of plasmids and phages covering the critical region.
A large open reading frame extends from the TATA box (not shown)
over the whole 5' region of the viral RNA. Starting at the AUG in posi-
tion 313-315 from the 5' end , the first 353 amino acids of the gag pre-
cursor polypeptide can be predicted.As the N-terminal end of this
protein has not been sequenced the assignment of the gag initiation
codon remains to be determined. However it has been recently shown that
the gag precursor protein of MMTV is myristylated (22). The acceptor
site for this protein-modification has been shown to be a glycine resi-
due and myristylation has been found at the N-termini of retroviral gag
proteins (37). It is therefore very likely that the N-terminal sequence
of the pr76 precursor molecule is Met-Gly, corresponding to the two
codons found in position 313-318 of the viral RNA. The next initiation
codon in position 502-504 is not followed by a glycine residue and could
not be modified. For these reasons we assume that the first possible
initiation codon is used for the translation of the gag gene product.
In the derived amino acid sequence three possible cleavage sites for a
trypsin-like protease are observed. The first one is found after amino
acid 59, the second after amino acid 187 and the third one after amino
acid 232. If gag-precursor cleavage is conservative as has been observed
frequently (38) and if only two of these sites were used, peptides of 59
and 128 or 173 amino acids would be generated. These are slightly
shorter than the molecular weights of plO and p21 determined. In the
processing of the N-terminal part of the murine leukemia virus gag-
precursor cleavage sites between an aromatic residue and proline are
used (38). Two such sequences are found at positions 81 and 270. If
these processing sites were used peptides of 81 and 188 amino acids
would be created. These values correspond better to the ones observed
for plO and p21.
Several functional features common to retroviruses were located in
the sequenced fragments. These include the terminal repeat of 11 nucleo-
tides at the 5' and 3' end of viral RNA (9) and a pyrimidine-rich repe-
titive sequence (435-452 nucleotides from the 5' end) which might be
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involved in the dimer linkage structure found between two viral RNA
molecules (29, 30).
The 5' splicing site for the subgenomic mRNA's, most of which is
4.4 kb env mRNA (33), was located at nucleotide 288 from the 5' end of
the viral RNA. The same 5' splicing site has been identified for the 1.7
kb mRNA coding for the putative LTR protein (19). The subgenomic mRNAs
do not include the AUG of the gag gene and contain their own initiation
codon (1-4, 18). They also miss the hypothetical dimer linkage structure
and should therefore not be efficiently packaged into virus particles.
The colinearity of the cloned DNA with RNA from infected cells was
also examined, using the Si nuclease assay under stringent conditions.
This method should allow the detection of small deletions or rearrange-
ments in the cloned DNA. We were unable to detect such defects and
therefore conclude that the complete DNA clone used in our previous
transfection experiments and the subgenomic DNA fragments sequenced here
are largely colinear with viral RNA isolated from infected cells. This
is in agreement with our previous observation that precursor poly-
peptides of the correct length are synthesized in cells transfected with
cloned MMTV DNA (28, 35, 36).
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